Large-scale testing (Phase 3)Study completedNCT07069309
What this trial is testing
Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
Who this might be right for
COVID-19SARS-COV-2 Infection
BioNTech SE 774